Skip to content
Menu

Ellie Menkaure

6 posts

Posts (6)

Ellie Menkaure NRXP 5 years ago #1

RESULTS please stop posting misinformation. You obviously don’t know how journal publications go ESPECIALLY when it is in pre-print. The authors of the article are Principal Investigators of the trial that work at different clinics (which recruited the patients for the trials. They are not employees of $NRXP. Yes, they have to include JJ as an author but that doesn’t mean he had read the article especially since it hasn’t been submitted for publication. Stop spreading conspiracy theories as to why there was a typo months ago announcing approval in a DRAFT of an article written by a bunch of PIs.

Ellie Menkaure NRXP 5 years ago #2

All CAPS person, an employee of $NXRP did not write the preprinted article. It was a Principal Investigator at one of the sites. They made a mistake and probably didn’t fully understand the EUA submission statuses yet. Not as big of a deal as you are making it out to be. It was corrected. Move on! If you don’t like the company and you don’t trust them, then pick another stock. Many many other stocks to choose from.

Ellie Menkaure NRXP 5 years ago #3

$NRXP Why are people posting conspiracy theories about the Pfizer vaccine on this discussion? If you don’t know how clinical trials work or how to find reliable scientific articles, stop spreading misinformation. Go read the clinical trial synopsis for the Pfizer vaccine trial on clinicaltrials.gov. The length of time they are collecting data and the antibody measurements are listed as secondary outcome measures. https://clinicaltrials.gov/ct2/show/NCT04368728. The trial got fast track designation by the FDA, the trial had unique advantages in that there was a global outbreak (east exposures) and they had 44,000 participants (typical vaccine trials are 3,000-6,000). They also did the phases in parallel. They have plenty of data to approve the vaccine. If you don’t know what it takes to get a drug approved, stop complaining that it shouldn’t have been approved.

Ellie Menkaure NRXP 5 years ago #4

All Caps person. FDA told Novartis to hold off on submission for EUA approval because there are manufacturing delays. $NRXP just did a DSMB meeting which means they just submitted additional data to the FDA. FDA might have requested additional data. As for 140 patients in 4 months from 35 sites, obviously you don’t know anything about clinical trials. Those aren’t bad numbers given how specific of a population this is targeting.

Ellie Menkaure NRXP 5 years ago #5

Stop posting all caps about the pre-published article if you don’t know how research works. The article is on a website where abstracts can be posted for public access months or even years before they are published in a reputable peer reviewed journal. The authors of the abstract are Principal Investigators (contracted to run the clinical trial at their hospital or research center). I highly doubt the mistake was on purpose by the actual writers of the abstract. More than likely, Dr. Javitt had not reviewed the abstract (even though he is listed as 3rd author). The statement in the article is accurate (Emergency use approval in Georgia and it has expanded access use authorization in the US). There are typos all over in this article so I wouldn’t base everything on this since it obviously hasn’t been thoroughly reviewed (probably by most of the authors).

Ellie Menkaure NRXP 5 years ago #6

Okay bought this in the 10s and been watching for weeks. EUA is back logged. They have used EUA over 600 times during the pandemic. Now, couple things going on with NRXP aviptadil is 1. Remdesivir is currently being used as a treatment and has already been approved and has manufacturing all set up. Aviptadil has been used for expanded access (which means whichever hospitals they chose in their clinical trial will be the only sites that can administer the drug to them). This means it is still very limited access. 2. NRXP has submitted to the FDA twice now for EUA. It is over the 60 days and it sounds like the FDA requested more data. I was wondering about this since the they are basing the efficacy on less than 200 patients. If you look at remdesivir, their study published in NEJM had 1062 in their studies (however the drug was already readily available). My guess is, FDA asked for data on more subjects. It is also a possibility the FDA will request data comparing aviptadil vs. remdesivir vs. placebo. Or maybe not. NRDX has people who used to work for the FDA on their board. I am sure those individuals reviewed the data prior to submitting to the FDA because they want to avoid getting rejected twice. Either way, given this companies deals with other companies and process in place for large manufacturing, I think this company is still a good buy.